Clinical trials: Liver Hypertrophy
Gastroesophageal Varices Hemorrhage, Colorectal Cancer
Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices Hemorrhage, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524676
- Testing
- Individualized Treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Zhongshan Hospital
Gaucher Disease
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued…
- Trial name
- NCT00962260
- Testing
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Where
- 15 sites in United States, Israel
- Sponsor
- Pfizer
Portal Vein Embolization, Liver, Hypertrophy
Comparison of N-butyl-cyanoacrylate and Micro Parti-cles Effect in Inducing Liver Hypertrophy After PVE
The aim of this study is to compare hypertrophy of the FLR after PVE with microparticles to hypertrophy after PVE with cyanoacrylate in a material large enough to answer the study question.
- Trial name
- NCT05660759
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 265 people
- Sponsor
- Linkoeping University
Liver Metastases, Liver Cancer
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
Liver resection is the treatment of choice in patients with malignant liver lesions. Unfortunately, the surgery is not always an option, as in same patients the future remnant liver (FRL) is too small to supply all the functions.
- Conditions
- Liver Metastases, Liver Cancer, Liver Neoplasms, Liver Metastasis Colon Cancer
- Trial name
- TANGO-LIVER (NCT06050200)
- Testing
- PVE, LVD, ALPPS
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Medical University of Warsaw
Obesity, Overfeeding
Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation
To investigate metabolic and molecular response to fatty acid-specific overfeeding in overweight subjects, in relation to changes in ectopic fat, lean tissue mass and insulin sensitivity
- Conditions
- Obesity, Overfeeding, Muscle Mass, Body Composition
- Trial name
- LIPOGAIN-2 (NCT02211612)
- Testing
- PUFA-group, SFA-group
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Liver Tumours, Liver Cancer (Primary and Metastatic)
Italian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy
The goal of this national mutlticenter observational study is to learn and describe trends over time in the use of techniques for inducing hepatic hypertrophy in Italy.
- Conditions
- Liver Tumours, Liver Cancer (Primary and Metastatic), Liver Resection, Liver Hypertrophy
- Trial name
- I-GROWtoh (NCT07445412)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Farber's Lipogranulomatosis, Ceramidase Deficiency
Biomarker for Farber Disease (BioFarber)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood
- Conditions
- Farber's Lipogranulomatosis, Ceramidase Deficiency, Hepatomegaly, Splenomegaly
- Trial name
- BioFarber (NCT02298634)
- Where
- 3 sites in Egypt, Germany and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Locally Advanced Malignant Liver Disease
ALPPS: Safety, Feasibility and Efficacy at a Single Center
The possibility to achieve a curative resection in patients with liver malignancies is limited by the future liver remnant (FLR).
- Trial name
- NCT02164292
- Testing
- ALPPS
- Where
- Argentina
- Volunteers
- 30 people
- Sponsor
- Hospital Italiano de Buenos Aires
Chronic Liver Disease
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses.
- Trial name
- NCT05532124
- Testing
- LAENNEC (Human Placenta Hydrolysate), normal saline
- Where
- 7 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Green Cross Wellbeing
Polycystic Liver Disease, Hepatomegaly
Lanreotide as Treatment of Polycystic Livers
To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney, Autosomal Dominant
- Trial name
- LOCKCYST (NCT00565097)
- Testing
- Lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 38 people
- Sponsor
- Radboud University Medical Center
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Gastroesophageal Varices, Colorectal Cancer
Early Diagnosis of Oxaliplatin-induced Portal Hypertension
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer.
- Conditions
- Gastroesophageal Varices, Colorectal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT04524650
- Testing
- the level of vWF
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Zhongshan Hospital
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Colorectal Cancer Liver Metastases
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE
Brief Summary: Some colorectal liver metastases can only be resected after inducing liver regeneration by portal vein embolization (PVE) to increase size function of the future liver remnant (FLR).
- Trial name
- DRAGON (NCT04272931)
- Testing
- Portal and Hepatic Vein Embolization
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 111 people
- Sponsor
- Maastricht University
Major Hepatectomy
Segment IV Hypertrophy After Liver Venous Deprivation
before major hepatectomy, in case of insufisant future liver remanent volume or function, portal embolization is a routinely used method to enable growth of the future liver remnant.
- Trial name
- NCT04370132
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cancer, Cancer of the Liver
4D Phase Contrast MR: Hypertrophy in Liver Cancer
The investigators hypothesize that 4Dimensional Phase Contrast Magnetic Resonance Angiography (4D PC MRA) evaluation of portal venous flow predicts underlying liver function and hypertrophic potential in patients with liver…
- Trial name
- NCT02618447
- Testing
- 4Dimensional Phase Contrast Magnetic Resonance Angiography, Portal vein embolization
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Splenomegaly, Hepatomegaly
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Gaucher Disease from blood (plasma)
- Trial name
- BioGaucher (NCT01331642)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Liver Resection, Cancer
Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)
The aim of this study is to compare two different techniques (portal vein embolization and radiofrequency assisted liver partition with portal vein ligation) for increasing liver volume prior to major liver resection.
- Trial name
- REBIRTH (NCT02216773)
- Testing
- Radiofrequency assisted liver partition with portal vein ligation (RALPP), Portal vein embolization (PVE)
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Imperial College London